• 107
  • 14
  • 收藏

Novavax slid nearly 20% in morning trading as the company was facing issues with the purity of its vaccine candidate

Tiger Newspress2021-10-20

Novavax slid nearly 20% in morning trading as the company was facing issues with the purity of its vaccine candidate.According to reports, Novavax has been unable to consistently prove it can manufacture a vaccine shot that meets the required quality standards.

The Food and Drug Administration discusses purity levels with each manufacturer, but each batch of the COVID-19 vaccine is supposed to be at least 90% pure.

Novavax has reportedly struggled to maintain purity levels that are close to the 90% threshold. The company recently showed purity levels around the 70% range, per reports. 

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

举报

评论14

  • RO8
    ·2021-10-21
    Buy buy buy
    回复
    举报
  • Jstan
    ·2021-10-21
    Like too
    回复
    举报
  • Alan_Goh
    ·2021-10-20
    Pardon my ignorance .. does Novavax engage a manufacturer to manufacture its vaccine ("fabless")? I know Pfizer has its own manufacturing facilities. Though might be of no fault of Novavax, the time-to-market delay would mean opportunity cost and reputation loss.. I hope the issues can be resolved asap
    回复
    举报
    收起
    • YoungYun
      It is mainly because the method used to test the purity of the new crown vaccine does not meet the standards of the regulatory agency.
      2021-10-20
      回复
      举报
    • Qqbear
      Yes they are partnering with Serum Institute
      2021-10-21
      回复
      举报
  • plasticbag
    ·2021-10-20
    Ok
    回复
    举报
    收起
  • PanaCota
    ·2021-10-20
     Ok
    回复
    举报
  • BBBBBBBBBB
    ·2021-10-20
    Ok
    回复
    举报
  • MT8
    ·2021-10-20
    Great ariticle, would you like to share it?
    回复
    举报
  • MT8
    ·2021-10-20
    https://ir.novavax.com/Novavax-Reconfirms-Confidence-in-Regulatory-Filing-Timelines-and-Manufacturing-Quality
    回复
    举报
  • ElonTong
    ·2021-10-20
    Sharks
    回复
    举报
  • Enigmatrade
    ·2021-10-20
    Gg.
    回复
    举报
    收起
    • Eileena
      sigh
      2021-10-20
      回复
      举报
  • 7983eeb5
    ·2021-10-20
    Like pls
    回复
    举报
    收起
    • jo88
      ok
      2021-10-20
      回复
      举报
  • Praveenh
    ·2021-10-20
    Ok
    回复
    举报
    收起
    • 7983eeb5
      ok
      2021-10-20
      回复
      举报
  • lineasy2
    ·2021-10-20
    This is bad for them as they may have to resubmit everything
    回复
    举报
  • HeroSmurf
    ·2021-10-20
    Gg
    回复
    举报
    收起
 
 
 
 

热议股票

 
 
 
 
 

7x24